For the third quarter of the fiscal year ending March 2026, net sales amounted to 57,617 million yen (24.2% decrease year-over-year), operating income was 554 million yen (97.8% decrease year-over-year), and net income attributable to owners of parent was 1,398 million yen (92.7% decrease year-over-year).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4521","jir_company_name":"Kaken Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-02-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4521-20260206-01.pdf","jir_short_summary":"For the third quarter of the fiscal year ending March 2026, net sales amounted to 57,617 million yen (24.2% decrease year-over-year), operating income was 554 million yen (97.8% decrease year-over-year), and net income attributable to owners of parent was 1,398 million yen (92.7% decrease year-over-year).","jir_summary":"### Performance Overview\nDuring the cumulative consolidated third quarter period of the fiscal year ending March 2026, the Kaken Pharmaceutical Co., Ltd. Group recorded net sales of 57,617 million yen (24.2% decrease year-over-year), operating income of 554 million yen (97.8% decrease year-over-year), and net income attributable to owners of parent of 1,398 million yen (92.7% decrease year-over-year), resulting in a decline in both revenue and profit. The primary factors include a reactionary decrease in one-time income from the transfer of intellectual property rights for NM26 and license agreements for the STAT6 inhibitor, the transition of the onychomycosis treatment agent \"Klenafin\" to authorized generic products, and an increase in R&D expenses (15,645 million yen, up 48.2% year-over-year). The equity ratio improved to 82.6% compared to the end of the previous period.\n\n### Segment Trends and Future Outlook\nIn the pharmaceutical segment, domestic pharmaceutical operations experienced a decrease in revenue due to drug price revisions and competitive products, whereas the agricultural chemicals business saw increased sales driven by the core product \"Polyoxin\" and others. Overseas sales amounted to 7,880 million yen, down 66.7% year-over-year. The real estate business posted net sales of 1,915 million yen (3.9% increase year-over-year) due to higher rental income. The full-year earnings forecast remains unchanged at net sales of 86,300 million yen, operating income of 2,100 million yen, and net income attributable to owners of parent of 2,300 million yen. In R&D, the phase III trials of \"KP-001\" and \"KAR\" achieved primary endpoints, and multiple license agreements were concluded to strengthen the foundation for future growth.","jir_financial_highlights":"Net Sales: 57,617 million yen (24.2% decrease year-over-year)\nOperating Income: 554 million yen (97.8% decrease year-over-year)\nOrdinary Income: 1,172 million yen (95.5% decrease year-over-year)\nNet Income Attributable to Owners of Parent: 1,398 million yen (92.7% decrease year-over-year)\nResearch and Development Expenses: 15,645 million yen (48.2% increase year-over-year)\nEquity Ratio: 82.6% (Increased from 80.2% at the end of the previous consolidated fiscal year)\nNumber of Issued Shares (End of Period): 44,139,730 shares (Unknown)\nNumber of Treasury Shares (End of Period): 6,271,390 shares (Decreased year-over-year)","jir_category":"","jir_hashtags":"#KakenPharmaceuticalCoLtd, #FinancialSummary, #JapaneseStocks","jir_key_figures":"Net Sales: 57,617 million yen (24.2% decrease year-over-year)\nOperating Income: 554 million yen (97.8% decrease year-over-year)\nNet Income Attributable to Owners of Parent: 1,398 million yen (92.7% decrease year-over-year)","jir_meta_title":"Kaken Pharmaceutical Q3 FY2026 Financial Results: Net Sales of 57,617 Million Yen, Down 24.2% Year-over-Year","jir_meta_description":"Kaken Pharmaceutical Co., Ltd. Q3 FY2026 financial summary. Net sales of 57,617 million yen, operating income of 554 million yen, and net income attributable to owners of parent of 1,398 million yen, all significantly down year-over-year. R&D expenses increased to 15,645 million yen. More details on the official website.","jir_og_title":"Kaken Pharmaceutical Announces Q3 FY2026 Financial Summary","jir_og_description":"Kaken Pharmaceutical Co., Ltd. Q3 FY2026 financial summary reporting decreases in sales and profits year-over-year and increased R&D expenses.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Sales Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 FY2025\\\",\\\"Q3 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[75990,57617],\\\"backgroundColor\\\":\\\"#4e73df\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Operating Income Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 FY2025\\\",\\\"Q3 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[25420,554],\\\"backgroundColor\\\":\\\"#1cc88a\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 FY2025\\\",\\\"Q3 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[19175,1398],\\\"backgroundColor\\\":\\\"#f6c23e\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"rd_expense_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Research and Development Expenses Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 FY2025\\\",\\\"Q3 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"R&D Expenses\\\",\\\"data\\\":[10557,15645],\\\"backgroundColor\\\":\\\"#e74a3b\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Net Sales Breakdown by Segment for Q3 FY2026\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Pharmaceuticals\\\",\\\"Real Estate Business\\\"],\\\"datasets\\\":[{\\\"data\\\":[55702,1915],\\\"backgroundColor\\\":[\\\"#4e73df\\\",\\\"#1cc88a\\\"]}]}}\"}]","ir_related_company":9082,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-25643","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n